Branko Sreckovic1, Vesna Dimitrijevic Sreckovic2, Ivan Soldatovic3, Emina Colak4, Mirjana Sumarac-Dumanovic2, Hristina Janeski5, Nenad Janeski6, Jasna Gacic7, Igor Mrdovic8. 1. Department of Internal Medicine, Clinical Center of Bezanijska kosa, Belgrade, Serbia. Electronic address: b.sreckovic65@gmail.com. 2. Clinic for Endocrinology, Diabetes and Metabolic Diseases, Faculty of Medicine, Belgrade University, Belgrade, Serbia. 3. Institute for Medical Statistics and Informatics, Faculty of Medicine, Belgrade University, Belgrade, Serbia. 4. Institute of Medical Biochemistry, Clinical Center of Serbia, Belgrade, Serbia. 5. University Children's Hospital, Belgrade, Serbia. 6. Clinical Center Zemun, Belgrade, Serbia. 7. Department of Surgery, Clinical Center of Bezanijska kosa, Belgrade, Serbia. 8. Clinic for Cardiovascular Diseases, Faculty of Medicine, Belgrade University, Belgrade, Serbia.
Abstract
BACKGROUND: It has been documented that patients with metabolic syndrome (MS) and vascular complications have higher homocysteine levels. Hyperhomocysteinemia correlates with IR, increasing oxidative stress, which causes lesions of vascular endothelium leading to endothelial dysfunction, hypertension and atherosclerosis. OBJECTIVE: The objectives of the study were to examine homocysteine values, along with cardiovascular risk factors (lipid and apolipoprotein status, CRP, blood pressure), indicators of renal function (microalbuminuria/24h), glucose regulation and insulin resistance (glucose and insulin level, HbA1c, HOMA-IR, uric acid) and anthropometric parameters (BMI, WC, HC, WHR) in patients with and without MS as a correlation between homocysteine and MS factors. METHODS: The study included obese and overweight individuals, aged of 30-75 yrs. classified into two groups: with MS (n=35) and without MS (n=41). RESULTS: Patients with MS had increased WC, BMI, BP, glycaemia, HOMA-IR, TG, CRP, microalbuminuria, homocysteine and decreased HDL-C (p<0.05). Statistically significant difference between groups was found for WC, BMI, sBP and dBP, TG, HDL-C (p<0.01) and glycaemia, CRP, Apo B, HOMA-IR (p<0.05). Significant positive correlations were found between homocysteine and sBP (p=0.036), dBP (p=0.04), Apo B (p=0.038) and hyperlipoproteinemia (type IIa, type IIb and type IV) (p=0.04). CONCLUSION: Patients with MS had increased abdominal obesity, hypertension, hypertriglyceridemia, inflammation factors, IR, homocysteine and microalbuminuria as markers of endothelial dysfunction. A correlation between homocysteine and hypertension and hyperlipoproteinemia showed that homocysteine could be used as a potential marker for atherosclerosis progression.
BACKGROUND: It has been documented that patients with metabolic syndrome (MS) and vascular complications have higher homocysteine levels. Hyperhomocysteinemia correlates with IR, increasing oxidative stress, which causes lesions of vascular endothelium leading to endothelial dysfunction, hypertension and atherosclerosis. OBJECTIVE: The objectives of the study were to examine homocysteine values, along with cardiovascular risk factors (lipid and apolipoprotein status, CRP, blood pressure), indicators of renal function (microalbuminuria/24h), glucose regulation and insulin resistance (glucose and insulin level, HbA1c, HOMA-IR, uric acid) and anthropometric parameters (BMI, WC, HC, WHR) in patients with and without MS as a correlation between homocysteine and MS factors. METHODS: The study included obese and overweight individuals, aged of 30-75 yrs. classified into two groups: with MS (n=35) and without MS (n=41). RESULTS:Patients with MS had increased WC, BMI, BP, glycaemia, HOMA-IR, TG, CRP, microalbuminuria, homocysteine and decreased HDL-C (p<0.05). Statistically significant difference between groups was found for WC, BMI, sBP and dBP, TG, HDL-C (p<0.01) and glycaemia, CRP, Apo B, HOMA-IR (p<0.05). Significant positive correlations were found between homocysteine and sBP (p=0.036), dBP (p=0.04), Apo B (p=0.038) and hyperlipoproteinemia (type IIa, type IIb and type IV) (p=0.04). CONCLUSION:Patients with MS had increased abdominal obesity, hypertension, hypertriglyceridemia, inflammation factors, IR, homocysteine and microalbuminuria as markers of endothelial dysfunction. A correlation between homocysteine and hypertension and hyperlipoproteinemia showed that homocysteine could be used as a potential marker for atherosclerosis progression.
Authors: F Cicone; M G Santaguida; G My; G Mancuso; A Papa; R Persechino; C Virili; N Brusca; A Tofani; F Scopinaro; M Centanni Journal: J Endocrinol Invest Date: 2017-12-29 Impact factor: 4.256
Authors: Eva-Maria Navarrete-Muñoz; Jesus Vioque; Estefanía Toledo; Alejando Oncina-Canovas; Miguel Ángel Martínez-González; Jordi Salas-Salvadó; Dolores Corella; Montserrat Fitó; Dora Romaguera; Ángel M Alonso-Gómez; Julia Wärnberg; J Alfredo Martínez; Luís Serra-Majem; Ramon Estruch; Francisco J Tinahones; José Lapetra; Xavier Pintó; Josep A Tur; José López-Miranda; Aurora Bueno-Cavanillas; Pilar Matía-Martín; Lidia Daimiel; Vicente Martín Sánchez; Josep Vidal; Ana Isabel de Cos Blanco; Emili Ros; Javier Diez-Espino; Nancy Babio; Rebeca Fernandez-Carrion; Olga Castañer; Antoni Colom; Laura Compañ-Gabucio; Itziar Salaverria Lete; Edelys Crespo-Oliva; Itziar Abete; Laura Tomaino; Rosa Casas; José Carlos Fernandez-Garcia; José Manuel Santos-Lozano; Iziar Sarasa; José M Gámez; José M Antonio Garcia-Rios; Sandra Martín-Pelaez; Miguel Ruiz-Canela; Andrés Díaz-López; Raul Martinez-Lacruz; Maria Dolors Zomeño; Elena Rayó; Cristina Gisbert Sellés; Silvia Canudas; Albert Goday; Manoli García-de-la-Hera Journal: Eur J Nutr Date: 2020-08-24 Impact factor: 5.614